NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Sinovac Biotech Ltd (NASDAQ: SVA) concerning possible violations of federal securities laws.
On December 21, 2016, an article published by SeekingAlpha.com revealed that Sinovac's Chairman and Chief Executive Officer, Weidong Ying, paid bribes to the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration and his wife, to help advance drug applications and evaluations. Sinovac later announced on May 16, 2017 that the Securities Exchange Commission is investigating the Company for alleged bribery mentioned in SeekingAlpha's article, and that Sinovac would not be able to file its annual financial results on time. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.